Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
Alexander M.M. Eggermont(University Medical Center Utrecht), Ulrich Keilholz(German Cancer Research Center), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Zvonko Kusić(Sisters of Charity Hospital), Cornelis J.A. Punt(Utrecht University), Axel Hauschild(University Hospital Schleswig-Holstein), Stefan Suciu(St James's University Hospital), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), François Salès(Institut Jules Bordet), Reinhard Dummer(University Hospital of Zurich), Jeremy Marsden(NIHR Surgical Reconstruction and Microbiology Research Centre), Rona M. MacKie(University of Glasgow), Wim H.J. Kruit(Erasmus MC), Alan Spatz(Jewish General Hospital), Martin Gore(Imperial College London), E. Musat(European Organisation for Research and Treatment of Cancer)
Cited by 642
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k